MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.
MoonLake tested a new medicine for a joint disease and got good results in late-stage testing. This means the company is making progress toward helping patients, and they have enough money to keep working for a few more years.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.